DexCom price to sales ratio DXCM
Market value divided by revenue over the last twelve months, since 2012.
- Today, Nov 3, 2026
- 6.4×
- 10-year median
- 12.1×
- Against its 10-year history
- 11th
- percentile: 0 is its lowest day, 100 its highest
- 10-year range
- 4.8× to 27.0×
- Peer median
- 3.0×
DexCom's price to sales ratio is 6.4× as of Nov 3, 2026.
That is below its ten-year median of 12.1×, lower than on 89% of days in the last ten years.
Over that time it ranged from 4.8× in Nov 2025 to 27.0× in Nov 2021.
The median for 9 medical device stocks of a similar size is 3.0×.
Price to sales ratio over time
The dashed line is the 10-year median and the shaded band the middle half of its days.
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 6.4× | 4.9× | 7.0× |
| 2025 | 5.8× | 4.8× | 8.8× |
| 2024 | 7.9× | 6.5× | 14.8× |
| 2023 | 14.1× | 9.2× | 17.6× |
| 2022 | 15.7× | 10.5× | 21.1× |
| 2021 | 22.4× | 15.9× | 27.0× |
| 2020 | 19.5× | 13.0× | 25.4× |
| 2019 | 14.8× | 9.5× | 15.4× |
| 2018 | 11.5× | 6.6× | 15.3× |
| 2017 | 7.5× | 6.1× | 13.5× |
| 2016 | 9.5× | 9.5× | 18.2× |
| 2015 | 18.7× | 17.8× | 25.1× |
| 2014 | 18.6× | 13.3× | 22.0× |
| 2013 | 17.8× | 10.6× | 18.1× |
| 2012 | 10.3× | 8.4× | 12.3× |
Against its peers
Companies in Medical - Devices nearest DexCom's size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| DXCMDexCom | 6.4× |
| GEHCGE HealthCare Technologies | 1.7× |
| EWEdwards Lifesciences | 8.4× |
| ZBHZimmer Biomet | 2.2× |
| BSXBoston Scientific | 3.0× |
| SYKStryker | 4.6× |
| MDTMedtronic | 3.4× |
| ABTAbbott Laboratories | n/m |
| LIVNLivaNova | 3.0× |
| ITGRInteger | 2.4× |
| Peer median | 3.0× |
Where DexCom ranks
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on DexCom
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.